epetirimod esylate
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00312286)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TLR7 and TLR8AGONIST
TLR7 and TLR8 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Cn1cnc2c(N)nc3cccnc3c21.CCS(=O)(=O)O.O- Mol. weight
- 369.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103808 ↗
Also known as
- 851b
- 851b
- 851b
- epetirimod esylate
- epetirimod esylate
- s-30563-35-65
- s-30563-35-65
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00117884 | Phase 2 | Apr 1, 2006 | Takeda |
| NCT00312286 | Phase 2 | Apr 1, 2006 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2006 |
1 organizations
Page 1 / 1